IL31RA and poikiloderma with neutropenia: These findings suggest that nemolizumab response is associated with modulation of inflammatory, neural, and epithelial signaling compared with placebo nonresponse, demonstrating the multifaceted role of IL-31RA inhibition in the treatment of PN.